Overview

Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)

Status:
Active, not recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to find out what effects (good and bad) immunotherapy treatment using the p53 vaccine (Ad.p53-DC) in combination with Nivolumab and Ipilimumab has on small cell lung cancer. Immunotherapy is a cancer therapy that uses the body's immune system to fight cancer cells. This study can be divided into three different phases: initial Induction Immunotherapy, Maintenance Immunotherapy and Retreatment.

Phase:

Phase 2

Details

Lead Sponsor:

H. Lee Moffitt Cancer Center and Research Institute

Collaborators:

Bristol-Myers Squibb
MultiVir, Inc.

Treatments:

Antibodies, Monoclonal
Ipilimumab
Nivolumab
Vaccines